Le Lézard
Classified in: Ebola virus, Health
Subjects: TDS, TRI, FVT

Tru-D SmartUVC to Exhibit at Premier Annual Breakthroughs Conference


MEMPHIS, Tenn., June 21, 2017 /PRNewswire/ -- Tru-D SmartUVC will join members of Premier at the Premier Annual Breakthroughs Conference and Exhibition in Washington, DC, June 27-30, 2017. Tru-D invites attendees to visit its booth #639 to learn about its cutting-edge technology that was recently validated by the only randomized clinical trial on UV disinfection.

Premier is a health care improvement company uniting an alliance of approximately 3,750 U.S. hospitals and more than 130,000 other provider organizations. As an industry leader, Premier has created one of the most comprehensive databases of actionable data, clinical best practices and efficiency improvement strategies. Tru-D has been a contracted supplier with Premier since 2014.

"Tru-D partners with health care facilities and hospital systems nationwide to reduce costly hospital-acquired infections while also saving on the bottom line through purchasing organizations such as Premier," said Chuck Dunn, CEO and president of Tru-D SmartUVC. "Our team looks forward to attending Premier Breakthroughs and demonstrating how Tru-D can provide a significant ROI while minimally impacting productivity."

Tru-D, short for "total room ultraviolet disinfection," is rolled in a hospital room after the environmental services staff cleans using traditional protocols. Used as an enhanced terminal room disinfection strategy, Tru-D is then activated by a remote control and begins administering a lethal cycle of UVC energy. Operating from a single placement in the room, Tru-D provides thorough room disinfection, killing up to 99.9 percent of harmful pathogens that can remain behind such as C. diff, MRSA, MERS, VRE, Ebola and many more. While the cycle is being completed, operators are free to tend to other tasks and are alerted via audio and/or text message when disinfection is complete.

"When evaluating various UV disinfection robots, it is important to consider total room disinfection versus partial room disinfection," said Dunn. "Tru-D's patented Sensor360 technology is able to compensate for room variables such as size, shape and contents to deliver the precise, lethal dose of UVC energy needed in each unique space."

Tru-D was the only device of its kind selected for the first-ever randomized, clinical trial on UVC disinfection because of its Sensor360 technology that eliminates any chance of human error in the disinfection process. Results of the landmark Benefits of Enhanced Terminal Room Disinfection (BETR-D) study proved that enhanced terminal room disinfection strategies that utilized Tru-D decreased the cumulative incidence of multidrug-resistant organisms by a cumulative 30 percent.

Tru-D invites attendees to their booth #639 to learn more about the gold standard in UV disinfection. For more information, visit Tru-D.com.

About Tru-D SmartUVC
Only Tru-D delivers an automated, measured dose of UVC light to consistently disinfect an entire room during a single cycle. Operating from a single position in the room, Tru-D ensures significant pathogen reduction in direct and shadowed areas. Validated by more than a dozen independent studies, Tru-D's automated, measured dosing capabilities and real-time usage-tracking features make it one of the most advanced UV disinfection systems available.

Christin Yates                                                  
Tru-D Public Relations                                
901-774-5771                                                 
[email protected]

SOURCE Tru-D SmartUVC


These press releases may also interest you

at 03:00
ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs, today announced an oral presentation at the upcoming Oligonucleotide & Peptide Therapeutics (TIDES) Conference...

at 02:32
With every successive year, the lines between medical devices and consumer electronics become increasingly blurred ? medtech companies seek to expand their reach beyond patients, and consumer electronics companies have targeted medical applications...

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...



News published on and distributed by: